Ticagrelor for the Prevention of Thrombotic Events in Acute Coronary Syndrome and Myocardial Infarction

Nanajaian, Mahadevan and PITCHAI, BALAKUMAR (2012) Ticagrelor for the Prevention of Thrombotic Events in Acute Coronary Syndrome and Myocardial Infarction. International Journal of Recent Advances in Pharmaceutical Research, 2. pp. 6-8. ISSN 2230-9306

[img]
Preview
PDF
Ticagrelor.pdf

Download (29kB) | Preview

Abstract

Acute coronary syndrome is associated with high morbidity and mortality. Acute coronary syndrome is concurred with unstable angina and heart attack as a result of reduced blood flow to the heart due to coronary thrombosis. Ticagrelor is an oral, reversible and directly acting inhibitor of the adenosine diphosphate (ADP) receptor-P2Y(12) that has a potential for platelet inhibition. The US Food and Drug Administration (FDA) approved ticagrelor in July 2011 for the prevention of thrombotic events in acute coronary syndrome or myocardial infarction. This review will discuss the potentials of ticagrelor for the management of acute coronary syndrome.

Item Type: Article
Subjects: Pharmaceutical Sciences
Divisions: College of Pharmacy > Pharmacy
Depositing User: MAHADEVAN NANJAIAN
Date Deposited: 13 Jun 2017 09:55
Last Modified: 13 Jun 2017 09:55
URI: http://eprints.kku.edu.sa/id/eprint/909

Actions (login required)

View Item View Item